Clinical Study on High-fiber Diet and Short-term Fasting in Melanoma Under Immunotherapy With Checkpoint Inhibition
NCT07680452 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2026-07-29
Summary
The treatment of melanoma has improved significantly in recent years. A modern form of cancer treatment known as immunotherapy with checkpoint inhibitors plays a key role in this. These drugs help the immune system better recognize and fight cancer cells. Nevertheless, it remains a challenge to maximize treatment effectiveness while minimizing side effects.
One possible approach to influencing treatment efficacy and tolerability is diet. A high-fiber diet, as recommended by the German Nutrition Society, increases the effectiveness of immunotherapy, in part through its influence on gut bacteria (the gut microbiota). Initial studies also show that short-term fasting (i.e., eating nothing or very little for a limited period) reduces the side effects of immunotherapy in mouse models and improves the tolerability of chemotherapy in humans.
This study investigates the feasability of a study on short-term fasting, in addition to a high-fiber diet in patiens with melanoma undergoing immunotherapy.
40 participants will follow a high-fiber diet based on the recommendations of the German Nutrition Society. Additionally, half of the participants will undergo periodic cycles of short-term fasting of 72h with each immunotherapy. Another 20 participants will not undergo any intervention and serve as a control group.
The goal is to determine whether this study concept is feasible. Exploratory outcomes include, quality of life, fatigue, tolerability of the therapy, impact on disease progression, immune system (flow cytometry) and gut bacteria (microbiome).
The results are intended to help understand whether targeted dietary measures can support the effectiveness of modern cancer treatments.
Conditions
- Melanoma (Skin Cancer)
Interventions
- BEHAVIORAL
-
High-Fiber Diet
High-Fiber Diet (\>35g/day) according to the German Nutrition Society (Deutsche Gesellschaft für Ernährung, DGE) for 6 months.
- BEHAVIORAL
-
High-Fiber Diet and Short-Term Fasting
High-Fiber Diet (\>35g/day) according to the German Nutrition Society (Deutsche Gesellschaft für Ernährung, DGE) and 72 hours of short-term fasting (max 400kcal/day) with every immunetherapy cycle for 6 months.
Sponsors & Collaborators
-
University Hospital Heidelberg
collaborator OTHER -
CHUM Microbiome Research Center Montréal
collaborator UNKNOWN -
Charite University, Berlin, Germany
lead OTHER
Principal Investigators
-
Anika Rajput, MD/PhD · Charité - Universitätsmedizin Berlin, Department of Dermatology, Venerology and Allergology
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-07-28
- Primary Completion
- 2028-07-05
- Completion
- 2028-12-05
Countries
- Germany
Study Locations
More Related Trials
-
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
NCT07148245 ·Status: RECRUITING
-
The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma
NCT04017897 ·Status: UNKNOWN ·Phase: PHASE2
-
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
NCT01709162 ·Status: TERMINATED ·Phase: PHASE2
-
Multiepitope Peptide Vaccination in Melanoma
NCT00153569 ·Status: UNKNOWN ·Phase: PHASE2
-
Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management
NCT06627595 ·Status: RECRUITING
-
Immune Profiles Evolution Under Immunotherapy for Melanoma
NCT04576429 ·Status: RECRUITING ·Phase: NA
-
Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker
NCT02740920 ·Status: TERMINATED ·Phase: PHASE2
-
Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma
NCT02694965 ·Status: COMPLETED
-
Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors
NCT00004016 ·Status: COMPLETED ·Phase: PHASE1
-
Immunotherapy Study for Patients With Stage IV Melanoma
NCT02054520 ·Status: TERMINATED ·Phase: PHASE2
-
Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens
NCT00204516 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Bone Loss in Melanoma Survivors Receiving Immunotherapy
NCT04516122 ·Status: TERMINATED
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
NCT04645680 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy
NCT00897520 ·Status: COMPLETED
-
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
NCT03698019 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Tipifarnib in Treating Patients With Metastatic Malignant Melanoma
NCT00060125 ·Status: COMPLETED ·Phase: PHASE2
-
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
NCT00017121 ·Status: COMPLETED ·Phase: PHASE1
-
CP-461 in the Treatment of Patients With Advanced Melanoma
NCT00060710 ·Status: TERMINATED ·Phase: PHASE2
-
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
NCT02094872 ·Status: COMPLETED ·Phase: PHASE2
-
CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma
NCT03727789 ·Status: TERMINATED ·Phase: PHASE1
-
The IRMI-FMT Trial
NCT04577729 ·Status: TERMINATED ·Phase: NA
-
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
NCT05169957 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase II Study of UCN-01 in Metastatic Melanoma
NCT00072189 ·Status: TERMINATED ·Phase: PHASE2
-
Intratumoral Injection Of Alpha-Gal Glycosphingolipids
NCT00668512 ·Status: COMPLETED ·Phase: PHASE1
-
Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012
NCT03784625 ·Status: COMPLETED ·Phase: EARLY_PHASE1